

1. (original) A system for the production of recombinant *N*-glycosylated target proteins, the system comprising a prokaryotic organism into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested *N*-glycosylation of the target protein, wherein said prokaryotic organism also contains the genetic information required for the expression of one or more recombinant target proteins.
2. (original) The system of claim 1, wherein the metabolic apparatus comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase that covalently links this oligosaccharide to specific residues of the desired target protein.
3. (amended) The system of ~~one of~~ claim[[s]] 1 or 2, wherein the prokaryotic organism is *Escherichia coli*.
4. (amended) The system of ~~one of~~ claim[[s]] 2 or 3, wherein the prokaryotic organism is producing *N*-glycanes with a specific structure which is defined by the type of the specific glycosyltransferases.
5. (original) A method of producing recombinant *N*-glycosylated target proteins, the method comprising the introduction of a genetic information encoding for a metabolic apparatus capable of carrying out the requested *N*-glycosylation of the target protein into a prokaryotic organism, wherein also the genetic information required for the expression of one or more recombinant target proteins is introduced into said prokaryotic organism.
6. (original) The method of claim 5, wherein the metabolic apparatus comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase, the OTase covalently linking this oligosaccharide to specific residues of the desired target protein.

7. (original) The method of one of claims 5 or 6, wherein the prokaryotic organism is *Escherichia coli*.
8. (amended) The method of ~~one of claim~~[[s]] 6 ~~or 7~~, wherein - by selection of specific glycosyltransferases - the prokaryotic organism is producing N-glycans with a specific structure which is defined by the type of the specific glycosyltransferases.
9. (amended) Utilization of the system of ~~one of claim~~[[s]] 1 ~~[[4]] or the method of one of claims 5-8~~ for the production of target proteins for the development of medicaments or for the production of medicaments for the treatment of humans or animals or plant.
10. (amended) Proteins for nutrition and/or pharmaceutical purposes, produced with the system of one of claims 1 ~~[[4]] or according to the method of one of claims 5 to 8~~.
11. (amended) Vaccines, Cytokines and the like medicaments for human or animals or plant, produced with the system of ~~one of claim~~[[s]] 1 ~~[[4]] or according to the method of one of claims 5 to 8~~.
12. (amended) Industrial enzymes, functional food, cosmetics, packaging materials or textiles comprising proteins produced with the system of ~~one of claim~~[[s]] 1 ~~4 or according to the method of one of claims 5-8~~.
13. (amended) Utilization of a medicament produced with the system of ~~one of claim~~[[s]] 1 ~~[[4]] or according to the method of one of claims 5-8~~ for the therapy of human or animal or plant diseases.
14. (new) The system of claim 2, wherein the prokaryotic organism is *Escherichia coli*.

15. (new) The system of claim 3, wherein the prokaryotic organism is producing N-glycans with a specific structure which is defined by the type of the specific glycosyltransferases.

16. (new) Utilization of the method of claim 5 for the production of target proteins for the development of medicaments or for the production of medicaments for the treatment of humans or animals or plant.

17. (new) Proteins for nutrition and/or pharmaceutical purposes, produced with the method of claim 5.

18. (new) Vaccines, Cytokines and the like medicaments for human or animals or plant, produced with the method of claim 5.

19. (new) Industrial enzymes, functional food, cosmetics, packaging materials or textiles comprising proteins produced with the method of claim 5.

20. (new) Utilization of a medicament produced with the method of claim 5 for the therapy of human or animal or plant diseases.